Michael Exton, CEO, highlighted, "Lexicon is advancing 3 very strong novel late-stage programs in the therapeutic areas of cardiometabolic disease and chronic pain." He emphasized progress in ...
THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results